Biopharmaceuticals Contract Manufacturing Market Report 2026

Biopharmaceuticals Contract Manufacturing Market Overview

• Biopharmaceuticals Contract Manufacturing market size has reached to $22.22 billion in 2025 • Expected to grow to $38.22 billion in 2030 at a compound annual growth rate (CAGR) of 11.6% • Growth Driver: Surging Demand For Personalized Medicine Propels Growth In Biopharmaceutical Contract Manufacturing Market • Market Trend: Monoclonal Antibody To Streamline And Optimize Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Biopharmaceuticals Contract Manufacturing Market?

Biopharmaceutical contract manufacturing refers to a process in which a biopharmaceutical company hires a third-party manufacturer to produce its drugs or biologic products on its behalf. It is utilized when pharmaceutical businesses employ the facilities of other companies to manufacture pharmaceuticals under their own brand. It is identical to private label or third-party production. The main products of biopharmaceutical contract manufacturing include biologics, monoclonal antibodies (MABs), recombinant proteins, vaccines, antisense, RNAi, molecular therapy and biosimilars. Monoclonal antibodies (MABs) refer to lab-made proteins that function in human bodies similarly to antibodies. They are sourced from mammalian and non-mammalian and the services offered include process development, fill and finish operations, analytical and QC studies, and packaging for applications in clinical and commercial purposes.

What Is The Biopharmaceuticals Contract Manufacturing Market Growth Forecast?

The biopharmaceuticals contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $38.22 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing demand for biosimilars manufacturing, rising investments in advanced biologics facilities, expansion of gene and cell therapy production, growing focus on flexible manufacturing models, increasing partnerships between pharma and CDMOs. Major trends in the forecast period include increasing outsourcing of biologic drug production, rising demand for monoclonal antibody manufacturing, growing use of single-use bioprocessing systems, expansion of fill-and-finish capabilities, enhanced focus on regulatory-compliant manufacturing.

Global Biopharmaceuticals Contract Manufacturing Market Segmentation

1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAI, And Molecular Therapy, Biosimilars 2) By Source: Mammalian, Non-mammalian 3) By Service: Process Development, Fill And Finish Operations, Analytical And QC studies, Packaging 4) By Application: Clinical, Commercial Subsegments: 1) By Biologics: Enzymes, Hormones, Antibodies 2) By Monoclonal Antibodies (MABs): Human MABs, Chimeric MABs, Murine MABs 3) By Recombinant Proteins: Insulin, Growth Factors, Cytokines 4) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines 5) By Antisense, RNAI, And Molecular Therapy: Antisense Oligonucleotides, RNA Interference Products, Gene Therapies 6) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulin, Biosimilar Growth Hormones

What Is The Driver Of The Biopharmaceuticals Contract Manufacturing Market?

The growing demand for personalized medicine is expected to propel the growth of the biopharmaceutical contract manufacturing market going forward. Personalized medicine refers to a customized healthcare approach that takes into account individual patient traits, including genetics, environment, and lifestyle, to enhance treatment effectiveness and outcomes. The increasing demand for personalized medicine is driven by several factors, including advancements in genomics, patient empowerment, and improved treatment efficacy. Contract manufacturers can create tailored production processes designed to fulfill the specific requirements of personalized therapies, accommodating small batch sizes and unique formulations. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine drives the growth of biopharmaceutical contract manufacturing market.

Key Players In The Global Biopharmaceuticals Contract Manufacturing Market

Major companies operating in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation

Global Biopharmaceuticals Contract Manufacturing Market Trends and Insights

Major companies operating in the biopharmaceutical contract manufacturing market are focused on developing monoclonal antibodies built on advanced platforms such as the go-to cell line platform to provide reliable services to customers. A go-to cell line platform is a standardized and optimized platform that allows for the rapid and efficient development of cell lines to produce biotherapeutics. For instance, in September 2023, KBI Biopharma Inc., a US-based life sciences company, launched the SUREmAb, a monoclonal antibody offering designed to enhance efficiency in development and manufacturing. Built on KBI's SUREtechnology Platform, SUREmAb aims to streamline processes, enabling rapid research cell bank development in nine weeks and transitioning from DNA to GMP drug substance in 11 months. The integration of KBI Biopharma and Selexis contributed to operational consolidation, optimizing monoclonal antibody development.

What Are Latest Mergers And Acquisitions In The Biopharmaceuticals Contract Manufacturing Market?

In May 2025, PCI Pharma Services Inc., a US–based contract development and manufacturing organization (CDMO) specializing in drug development, sterile fill finish, and advanced drug delivery, acquired Ajinomoto Althea, Inc. for an undisclosed amount. With this acquisition, PCI aimed to expand its sterile manufacturing footprint and scale advanced injectable and biologics production capabilities, particularly prefilled syringes, cartridges, and high potent formats, to better serve biopharma customers and broaden its manufacturing network. Ajinomoto Althea Inc. is a US–based sterile fill finish CDMO that specializes in aseptic fill finish and formulation services for clinical and commercial stage biopharmaceutical products, including customized oligonucleotides, peptides, and other complex injectables.

Regional Insights

North America was the largest region in the biopharmaceutical contract manufacturing market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biopharmaceuticals Contract Manufacturing Market?

The biopharmaceutical contract manufacturing market includes revenues earned by entities providing services such as formulation development, GMP manufacturing, and supply chain management. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biopharmaceuticals Contract Manufacturing Market Report 2026?

The biopharmaceuticals contract manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceuticals contract manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.